Identification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311401 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Serap Ozer Yaman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Trabzon Kanuni Training and Research Hospital, Faculty of Medicine, Trabzon University, 61030 Trabzon, Turkey. Hauptthemen laut MEDLINE: cdc25 Phosphatases, MicroRNAs, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by uncontrolled proliferation of myeloid cells. MicroRNAs (miRNAs), small noncoding RNAs, regulate post-transcriptional gene expression by degrading target mRNAs or repressing translation. Dysregulated miRNA expression has been implicated in various malignancies, including CML, where they can function as oncogenes or tumor suppressors. This study aimed to investigate the relationship between miR-122-5p and cell division cycle 25A (CDC25A) in CML and to elucidate the regulatory mechanisms of miR-122-5p. This study integrates bioinformatics analysis with in vitro RT-qPCR validation in K562 chronic myeloid leukemia cells to explore the potential regulatory relationship between miR-122-5p and CDC25A. mRNA expression profiles were retrieved from the GSE100026 dataset in the Gene Expression Omnibus (GEO), and differentially expressed genes were identified using GEO2R. Quantitative real-time PCR (RT-qPCR) was performed to measure miR-122-5p, CDC25A, and cyclin-dependent kinase 4 (CDK4) expression levels. Bioinformatics analyses (miRNeT, miRDIP, TargetScan, BioGPS, GeneMANIA, STRING) were applied to predict molecular interactions and functional pathways. Public RNA-seq datasets and in silico tools were used to prioritize candidates; RT-qPCR in a single CML cell line (K562) provided in vitro expression validation. In K562 cells, miR-122-5p expression was significantly reduced, while CDC25A and CDK4 were markedly upregulated. Bioinformatics tools confirmed CDC25A as a potential miR-122-5p target. Functional enrichment indicated CDC25A involvement in cell cycle regulation and apoptosis. These findings suggest that miR-122-5p functions as a tumor suppressor in CML by targeting CDC25A. Modulating the miR-122-5p/CDC25A axis may provide potential molecular targets for inhibiting CML progression through regulation of cell cycle pathways. Findings are exploratory and based on bioinformatics with limited in vitro expression confirmation; functional studies are required to establish causality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Trabzon Kanuni Training and Research Hospital, Faculty of Medicine, Trabzon University, 61030 Trabzon, Turkey.
- Laboratory for Radiobiology and Molecular Genetics, "VINČA" Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11000 Belgrade, Serbia.
- Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, 11000 Belgrade, Serbia.
- Department of Hematology, Mengücek Gazi Education and Research Hospital, 24100 Erzincan, Turkey.
- Department of Internal Medicine, Trabzon Kanuni Training and Research Hospital, Faculty of Medicine, Trabzon University, 61030 Trabzon, Turkey.
- Cellular and Molecular Radiation Oncology Laboratory, Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
ORCID-Profile: Serap Ozer Yaman, Nina Petrović, Ahmad Šami, Sema Misir
Zitieren
APA
Ozer Yaman, S., Petrović, N., Yaman, S., Akidan, O., Cimbek, A., Baycelebi, G., Srdić-Rajić, T., Šami, A., & Misir, S. (2025). Identification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311401
Vancouver
Ozer Yaman S, Petrović N, Yaman S, Akidan O, Cimbek A, Baycelebi G, et al. Identification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311401
BibTeX
@article{OzerYaman2025,
author = {Ozer Yaman, Serap and Petrović, Nina and Yaman, Selcuk and Akidan, Osman and Cimbek, Ahmet and Baycelebi, Gulsah and Srdić-Rajić, Tatjana and Šami, Ahmad and Misir, Sema},
title = {Identification of a Novel miR-122-5p/CDC25A Axis and Potential Therapeutic Targets for Chronic Myeloid Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311401}
}
EUVIMED